{
  "id": 5095446,
  "title": "Stifel reiterates Buy on Definium Therapeutics stock, $60 target",
  "url": "https://urgent.news/2026/09/02/stifel-reiterates-buy-on-definium-therapeutics-stock-60-target",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-02T13:37:02.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/stifel-reiterates-buy-on-definium-therapeutics-stock-60-target-93CH-4886287"
  },
  "original_language": "en",
  "account": "Definium Therapeutics Inc. remains a Buy recommendation from Stifel with a $60.00 price target, according to the latest update on Investing.com. Currently trading at $39.07, the stock has seen a 12% decline over the past week but has climbed 322% year-to-date. Analysts express optimism, with a consensus Strong Buy rating and targets ranging from $52 to $90. Stifel recently met with CEO Rob Barrow to discuss upcoming catalysts, such as a second phase 3 GAD readout anticipated later in the month. The firm highlighted clinical efficacy in their late-stage studies, particularly the Panorama study featuring a 50µg arm to enhance rigor and reduce bias. The primary success criterion is demonstrating a statistically significant difference between the 100µg dose and placebo. Definium plans to file jointly for MDD and GAD indications, contingent on a positive pre-NDA meeting. Financially, DFTX holds more cash than debt, per InvestingPro's assessment. The company's DT120 drug, an orally-disintegrating tablet for generalized anxiety disorder, showed positive results in its Phase 3 Voyage trial, meeting primary and secondary efficacy endpoints. This outcome has led to an increased price target from Canaccord Genuity (from $58 to $64) and a Buy rating from BofA Securities (currently at $75). Stifel's decision to maintain its Buy rating with a $60 target underscores continued confidence in Definium's drug candidate and its potential impact on treating brain health disorders.",
  "summary": null,
  "key_points": [
    "Stifel maintains Buy rating on Definium Therapeutics with $60 target",
    "Stock down 12% week-over-week but up 322% year-to-date",
    "Upcoming GAD readout and Panorama study drive optimism"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "DA Davidson reiterates Buy on Jack Henry stock after cyber incident",
        "url": "https://urgent.news/2026/09/02/da-davidson-reiterates-buy-on-jack-henry-stock-after-cyber-incident",
        "published": "2026-09-02T14:34:47.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}